Evidence map›Paper›PMID 28575485›Full record

ArticleNeuro-oncology2017

Adult IDH wild-type lower-grade gliomas should be further stratified.

Abudumijit Aibaidula, Aden Ka-Yin Chan, Zhifeng Shi, Yanxi Li, Ruiqi Zhang, Rui Yang, Kay Ka-Wai Li, Nellie Yuk-Fei Chung, Yu Yao, Liangfu Zhou and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 4 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 4 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.Archives of pathology & laboratory medicine · 2022
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Abudumijit AibaidulaDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Aden Ka-Yin ChanDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Zhifeng ShiDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Yanxi LiDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Ruiqi ZhangDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Rui YangDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Kay Ka-Wai LiDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Nellie Yuk-Fei ChungDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Yu YaoDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Liangfu ZhouDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Jinsong WuDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Hong ChenDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Ho-Keung NgDepartment of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China); Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Prince of Wales Hospital · CNChinese University of Hong Kong · CNFudan University · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAstrocytoma of the isocitrate dehydrogenase (IDH) wild-type gene is described as a provisional entity within the new World Health Organization (WHO) classification. Some groups believe that IDH wild-type lower-grade gliomas, when interrogated for other biomarkers, will mostly turn out to be glioblastoma. We hypothesize that not all IDH wild-type lower-grade gliomas have very poor outcomes and the group could be substratified prognostically.

methodsSeven hundred and eighteen adult WHO grades II and III patients with gliomas from our hospitals were re-reviewed and tested for IDH1/2 mutations. One hundred and sixty-six patients with IDH wild-type cases were identified for further studies, and EGFR and MYB amplifications, mutations of histone H3F3A, TERT promoter (TERTp), and BRAF were examined.

resultsEGFR amplification, BRAF, and H3F3A mutations were observed in 13.8%, 6.9%, and 9.5% of patients, respectively, in a mutually exclusive pattern in IDH wild-type lower-grade gliomas. TERTp mutations were detected in 26.8% of cases. Favorable outcome was observed in patients with young age, oligodendroglial phenotype, and grade II histology. Independent adverse prognostic values of older age, nontotal resection, grade III histology, EGFR amplification, and H3F3A mutation were confirmed by multivariable analysis. Tumors were further classified into "molecularly" high grade (harboring EGFR, H3F3A, or TERTp) (median overall survival = 1.23 y) and lower grade (lacking all of the 3) (median overall survival = 7.63 y) with independent prognostic relevance. The most favorable survival was noted in molecularly lower-grade gliomas with MYB amplification.

conclusionAdult IDH wild-type lower-grade gliomas are prognostically heterogeneous and do not have uniformly poor prognosis. Clinical information and additional markers, including MYB, EGFR, TERTp, and H3F3A, should be examined to delineate discrete favorable and unfavorable prognostic groups.

Indexed as

Genetic Predisposition to DiseaseAdultAgedBiomarkers, TumorBrain NeoplasmsFemaleGliomaHumansIsocitrate DehydrogenaseMaleMiddle AgedMutationNeoplasm GradingBiomarkers, TumorIsocitrate DehydrogenasegliomaIDH wild-typemolecular gradeMYB amplificationprognosis

Identifiers

PMID28575485
PMCPMC5596181
OpenAlexW2608192684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.